Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 1
2018 1
2021 1
2022 2
2023 4
2024 4
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer.
de Vos II, Meertens A, Hogenhout R, Remmers S, Roobol MJ; ERSPC Rotterdam Study Group. de Vos II, et al. Eur Urol. 2023 Oct;84(4):426-434. doi: 10.1016/j.eururo.2023.03.016. Epub 2023 Apr 5. Eur Urol. 2023. PMID: 37029074 Free article. Clinical Trial.
Reducing Overtreatment of Prostate Cancer Patients: Revisiting the European Association of Urology Pretreatment Risk Group Classification Using Long-term Follow-up Data from the European Randomized Study of Screening for Prostate Cancer Rotterdam.
de Vos II, Rosenstand C, Hogenhout R, van den Bergh RCN, Remmers S, Roobol MJ; ERSPC Rotterdam Study Group. de Vos II, et al. Eur Urol Oncol. 2024 Nov 26:S2588-9311(24)00252-9. doi: 10.1016/j.euo.2024.11.004. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39603883 Free article.
From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life.
Hogenhout R, Remmers S, van Slooten-Midderigh ME, de Vos II, Roobol MJ; ERSPC Rotterdam Study Group. Hogenhout R, et al. Eur Urol Oncol. 2024 Aug;7(4):713-720. doi: 10.1016/j.euo.2023.08.011. Epub 2023 Sep 9. Eur Urol Oncol. 2024. PMID: 37690917 Free article. Clinical Trial.
Assessing the Cause of Death for Men with Prostate Cancer Using Official Mortality Statistics or a Dedicated Cause of Death Committee: Results from 30-year ERSPC Rotterdam Data.
Remmers S, de Vos II, Denijs FB, Leenen RCA, Lock TMTW, Noordzij A, Kirkels WJ, Bangma CH, Roobol MJ; ERSPC Rotterdam Study Group. Remmers S, et al. Eur Urol Open Sci. 2024 Nov 16;71:11-14. doi: 10.1016/j.euros.2024.10.021. eCollection 2025 Jan. Eur Urol Open Sci. 2024. PMID: 39641118 Free PMC article.
Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam.
Hogenhout R, de Vos II, Remmers S, Venderbos LDF, Busstra MB, Roobol MJ; ERSPC Rotterdam Study Group. Hogenhout R, et al. Eur Urol Open Sci. 2022 Jul 2;42:42-49. doi: 10.1016/j.euros.2022.06.004. eCollection 2022 Aug. Eur Urol Open Sci. 2022. PMID: 35911085 Free PMC article.
11 results